Jacobs Levy Equity Management, Inc Gritstone Bio, Inc. Transaction History

Jacobs Levy Equity Management, Inc

11 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2023 May 15, 2023	SELL	$2.13 - $3.74 $100,186 - $175,914	-47,036 Reduced 13.7%	296,312 $823,000
Q4 2022 Feb 14, 2023	SELL	$2.17 - $3.92 $1.76 Million - $3.19 Million	-812,916 Reduced 70.31%	343,348 $1.18 Million
Q3 2022 Nov 15, 2022	BUY	$2.46 - $4.75 $2.26 Million - $4.36 Million	917,090 Added 383.44%	1,156,264 $2.97 Million
Q2 2022 Aug 15, 2022	BUY	$1.77 - $4.34 $121,335 - $297,511	68,551 Added 40.18%	239,174 $579,000
Q1 2022 May 16, 2022	BUY	$4.03 - $12.19 $325,696 - $985,171	80,818 Added 89.99%	170,623 $703,000
Q3 2021 Nov 15, 2021	SELL	$6.41 - $13.54 $6,961 - $14,704	-1,086 Reduced 1.19%	89,805 $970,000
Q2 2021 Aug 16, 2021	BUY	$8.13 - $10.2 $8,829 - $11,077	1,086 Added 1.21%	90,891 $830,000
Q1 2021 May 17, 2021	SELL	$4.07 - $27.11 $243,223 - $1.62 Million	-59,760 Reduced 39.96%	89,805 $847,000
Q4 2020 Feb 16, 2021	SELL	$2.57 - $4.22 $21,318 - $35,004	-8,295 Reduced 5.25%	149,565 $589,000
Q3 2020 Nov 16, 2020	BUY	$2.63 - $8.09 $357,277 - $1.1 Million	135,847 Added 617.12%	157,860 $418,000
Q2 2020 Aug 17, 2020	BUY	$5.69 - $8.17 $125,253 - $179,846	22,013 New	22,013 $146,000

35.4M

395K

132K

Ticker GRTS
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 73,006,896
Market Cap $2.19M
Description
Gritstone bio, Inc., a clinical-stage biotechnology company, engages in developing immunotherapies against multiple cancer types and infectious diseases. Its lead product candidate is GRANITE, a neoantigen-based immunotherapy for the treatment of solid tumors, including metastatic non-small cell lung cancer, as well as gastroesophageal, bladder ...

Get notified when there are updates to the investment portfolio of Jacobs Levy Equity Management, Inc, based on Form 13F filings with the SEC.

Stay updated on Jacobs Levy Equity Management, Inc with notifications on news.